Clostridium difficile-associated diarrhea;Diarrea asociada a Clostridium difficile

Gastroenterologia y Hepatologia

Volumn 32, Issue 1, 2009, Pages 48-56

  Bujanda, Luis ^a   Cosme, Ángel ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antibiotics; Clostridium difficile; Diagnosis; Diarrhea; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; CEPHALOSPORIN; CHLORAMBUCIL; CISPLATIN; CLINDAMYCIN; COLESTYRAMINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IMMUNOGLOBULIN; LOPERAMIDE; MACROLIDE; METHOTREXATE; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SULFANILAMIDE; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG CHOICE; FECES; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION RISK; MORBIDITY; PATHOGENESIS; PSEUDOMEMBRANOUS COLITIS; REINFECTION; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; COLECTOMY; COLONOSCOPY; COMBINED MODALITY THERAPY; CROSS INFECTION; DIARRHEA; DNA, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; MALE; METRONIDAZOLE; PROBIOTICS; RECURRENCE; RISK FACTORS; SUPERINFECTION; VANCOMYCIN;

EID: 63149198816     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2008.02.003     Document Type: Article

References (50)

1. Finney J.M.T. Gastro-enterostomy for cicatrizing ulcer of the pylorous. Bull Johns Hopkins Hosp 4 (1893) 53-55
2. Hall I.C., and O'Toole E. Intestinal flora in newborn infant. Am J Dis Child 49 (1935) 309-402
3. Tedesco F.J., Barton R.W., and Alpers D.H. Clindamycin-associated colitis. A prospective study. Ann Intern Med 81 (1974) 429-433
4. Rifkin G.D., Silva Jr. J., Fekety F.R., and Sack R.B. Antibiotic induced colitis. Implication of a toxin neutralized by Clostridium sordelli antitoxin. Lancet 2 (1977) 1103-1106
5. George R.H., Simonds J.M., Dimock F., Brown J.D., Arabi Y., Shingawa N., et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. BMJ 1 (1978) 695
6. McFarland L.V., Beneda H.W., Clarridge J.E., and Raugi G.J. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 35 (2007) 237-253
7. Aronsson B., Mollby R., and Nord C.E. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis 151 (1985) 476-481
8. McFarland L.V., Mulligan M.E., Kwok R.Y.Y., and Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989) 204-210
9. Ramos A., Gazapo T., Murillas J., Portero J.L., Valle A., and Martín F. Brote de diarrea nosocomial por Clostridium difficile en un servicio de medicina interna. Enferm Infecc Microbiol Clin 16 (1998) 66-69
10. Pazos R., Isusi A., Fernández R., Barbeito L., Bravo A., Cantón I., et al. Brote nosocomial de diarrea por Clostridium difficile en un servicio de cirugía vascular. Enferm Infecc Microbiol Clin 21 (2003) 237-241
11. Borriello S.P., Honour P., Turner T., and Barclay F. Household pets as a potential reservoir for Clostridium difficile infection. J Clin Pathol 36 (1983) 84-87
12. Pepin J., Valiquette L., Gagnon S., Routhier S., and Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102 (2007) 2781-2788
13. McFarland L.V., Beneda H.W., Clarridge J.E., and Raugi G.J. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 35 (2007) 237-253
14. Loo W.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associaaated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
15. Anand A., and Glatt A.E. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Inf Dis 17 (1993) 109-113
16. Surawicz C.M. The acid test: is proton pump inhibitor theraphy and independent risk factor for Clostridium difficile-associated disease?. Gastroenterology 133 (2007) 355-357
17. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile-associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
18. Surawicz C.M. Emergency colectomy in severe Clostridium difficile-associated disease: the sooner the better for some. Gastroenterology 133 (2007) 718-720
19. Rupnik M., Kato N., Grabnar M., and Kato H. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 41 (2003) 1118-1125
20. Johnson S., Sambol S.P., Brazier J.S., Delmée M., Avesani V., Merrigan M.M., et al. International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol 41 (2003) 1543-1547
21. Viscidi R.P., and Bartlett J.G. Antibiotic-associated pseudomembranous colitis in children. Pediatrics 67 (1981) 381-386
22. Blossom D.B., and McDonald L.C. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 45 (2007) 222-227
23. García-López S., and Gomollón F. Colitis seudomembranosa. Gastroenterol Hepatol 21 (1998) 302-313
24. Adams S.D., and Mercer D.W. Fulminant Clostridium difficile colitis. Curr Opin Crit Care 13 (2007) 450-455
25. Pepin J., Routhier S., Gagnon S., and Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 42 (2006) 758-764
26. Zar F.A., Bakkanagari S.R., Moorthi K.M., and Davis M.B. A compaison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007) 302-307
27. Jacobs A., Barnard K., Fishel R., and Gradon J.D. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 80 (2001) 88-101
28. Lamontagne F., Labbe A.C., Haeck O., Lesur O., Lalancette M., Patino C., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245 (2007) 267-276
29. García A., Pérez J.L., Pulido A., Niubó J., Pérez P., and Martín R. Evaluación de cuatro métodos rápidos para la investigación de la capacidad toxigénica de las cepas de Clostridium difficile aisladas en un medio selectivo. Med Clin (Barc) 18 (2000) 109-112
30. Calvo J., Zarrabeitia R., García-Palomo D., Fariñas M.C., and Agüero J. Evaluación de tres métodos para el diagnóstico de la infección por Clostridium difficile. Enferm Infecc Microbiol Clin 19 (2001) 184-186
31. Peterson L.R., Manson R.U., Paule S.M., Hacek D.M., Robicsek A., Thomson Jr. R.B., et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of Clostridium difficile-associated diarrhea. Clin Infect Dis 45 (2007) 1152-1160
32. a ed (2006), Asociación Española de Gastroenterología, Barcelona 197-203
33. Apisarnthanarak A., Razavi B., and Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 35 (2002) 690-696
34. Fekety R., Silva J., Kaufman C., Buggy B., and Deery H.G. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 86 (1989) 15-19
35. De Isusi A.M., González E., Gayoso P., Gastelu-Iturri J., Barbeito L., and Fernández R. Diarrea associated with Clostridium difficile: experience at a secondary hospital. Med Clin (Barc) 121 (2003) 331-333
36. Musher D.M., Nuila F., and Logan N. The long-term outcome of treatment of Clostridium difficile colitis. Clinic Infect Dis 45 (2007) 523-524
37. Miller M.A. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 45 Suppl 2 (2007) 122-307
38. Mc Farland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101 (2006) 812-822
39. Hickson M., D'Souza A.L., Muthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335 (2007) 80
40. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002) 1769-1775
41. Johnson S., Schriever C., Galang M., Kelly C.P., and Gerding D.N. Interruption of recurrent Clostridium difficile associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44 (2007) 846-848
42. Louie T.J., Peppe J., Watt C.K., Johnson D., Mohammed R., Dow G., et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43 (2006) 411-420
43. Barker Jr. R.H., Daghr R., Davidson D.M., and Marquis J.K. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 24 (2006) 1525-1534
44. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53 (2004) 882-884
45. Murphy C., Vernon M., and Cullen M. Intraveous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 35 (2006) 85-86
46. Juang P., Skledar S.J., Zgheib N.K., Paterson D.L., Vergis E.N., Shannon W.D., et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control 35 (2007) 131-137
47. Van Dissel J.T., De Groot N., Hensgens C.M., Numan S., Kuijper E.J., Veldkamp P., et al. Obvien antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54 (2005) 197-205
48. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128 (2005) 764-770
49. Aas J., Gessert C.E., and Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36 (2003) 580-585
50. Lewis S., Burmeister S., and Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomised controlled study. Clin Gastroenterol Hepatol 3 (2005) 442-448